Chakravarti, A., Tyndall E, Palanichamy K, Mehta M, Aldape K, Loeffler J. The Impact of Molecular Profiling on Clinical Trial Design in Glioblastoma. Curr Opin Oncol. 2007 Jan;9(1):71-9.

Saia, G., Zhang, M., Depalo, V., Lautenschläger, T., Chakravarti, A. Molecular and Genetic Profiling of Prostate Cancer: Implications for Future Therapy. Curr Ca Th Rev. 2007 Feb, 3,1, pp.25-36

Chakravarti, A.; Zhang, M.; Khor, L-Y.; Pollack, A.; Shipley, W. The prognostic value of p16 in locally-advanced prostate cancer: a report from RTOG 9202. J. Clin Oncol 2007; 25(21): 3082-3089.

Stupp, R., Hegi, M.; Gilbert, M.; Chakravarti, A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J. Clin Oncol 2007; 25(26): 4127-4136.

Corn B; Moughan, J.; Knisely, J. Fox, S; Chakravarti, A; Yung, W.A.; Curran, W.J.; Robins,H.I.; Brachman, D.; Henderson, R.; Mehta, M.; Movsas, B. Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole brain radiotherapy with or without thalidomide on RTOG 0118. Int J Radiat Oncol Biol Phys. (in press).

Corn B; Moughan, J.; Knisely, J. Fox, S; Chakravarti, A; Yung, W.A.; Curran, W.J.; Robins,H.I.; Brachman, D.; Henderson, R.; Mehta, M.; Movsas, B. WBRT +/- thalidomide for brain metastases: Phase III trial. Int J Radiat Oncol Biol Phys. (in press).

Yoshimoto, K.; Dang, J.; Zhu, S.; Nathanson, D.; Huang, T.; Dumont, R. ; Seligson,D. ; Yong, B. ; Xiong, Z. ; Rao, N. ; Winther, H.; Chakravarti, A.; Bigner, D.; Cavenee, W.; Mellinghoff, I.; Horvath, S.; Cloughesy, T.; Mischel, P. Detection of EGFRvIII in routinely processed GBM clinical samples. Clin Ca Res (in press).

Chakravarti, A. Targeted Therapies for Malignant Gliomas. Adv Rad Oncol, (in press).

Chakravarti, A. Efforts to translate molecular and genetic profiling of gliomas into clinical trials. Curr Oncol Reports (in press).

Palanichamy, K.; Erkkinen, M.; Saia, G.; Chakravarti, A. Molecular and genetic profiling in gliomas. Discovery Medicine (in press).

Sher,D.; Henson, J.; Avutu, B.; Hochberg, F.; Batchelor, T.; Martuza, R.; Loeffler, J.; Chakravarti, A. The added value of concurrently-administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. J. Neurooncol. (accepted for publication).

Franks,D.; Mukherjee, N.; Black, P.; Loeffler,J.; Chakravarti, A. Stat-3 gene expression is associated with poor prognosis in GBM. Translational Oncogenomics (accepted for publication).

Zhai, G.; Malhotra, R.; Delaney, M; Drummond, K.; Chakravarti, A.* Radiation-induced RhoA activation increases cellular invasion and motility of glioblastoma cells via IGFR/AKT-dependent signaling. J. Neurooncol, 2006 Feb;76(3):227-37.

Chakravarti, A.; Erkkinen, M.; Nestler, U.; Stupp, R.; Mehta, M.; Aldape, K.; Gilbert, M.; Black, P.; Loeffler, J. Temozolomide-mediated radiation enhancement in gliomas: a report on underlying mechanisms. Clin Ca Res 2006; 12(15):4738-4746.

Cardinale, R.; Won, M.; Choucair, A.; Gillin, M.; Chakravarti, A.; Schultz, C.; Souhami, L.; Chen, A.; Pham, H.; Mehta, M. A phase II study of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1422-8.

Johnson, M.; Carrol, R.; Liu, F.; Chakravarti, A.; Kohane, I.; Maher, E.; Depinho, R.; Black, P. A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA as a mitogen in glioblastoma. Cancer Res . 2006 Nov 15;66(22):10815-23.

Chakravarti, A. Interpretation of molecular marker data in the modern era. Int J. Radiat. Oncol. Biol. Phys. 2006; 66(1):1-2.

Zhang, M., Chakravarti, A. Novel radiation-enhancing agents in malignant gliomas. Semin Radiat Oncol. 2006 Jan;16(1):29-37.

Palanichamy, K., Erkkinen, M., Chakravarti, A. Predictive and Prognostic Markers in Human Gliomas. Curr Tr Opt Oncol. 2006 Nov;7(6):490-504.

Siker, M.; Chakravarti, A.; Mehta, M. Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplasticglioma? Crit Rev Oncol Hematol. 2006 Nov;60(2):99-111.

Cardinale, R.; Won, M.; Choucair, A.; Gillin, M.; Chakravarti, A.; Schultz, C.; Souhami, L.; Chen, A.; Pham, H.; Mehta, M. A phase II study of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J of Radiat Oncol Biol Phys 2006; 65(5):1422-1428.

Johnson, M.; Carrol, R.; Liu, F.; Chakravarti, A.; Kohane, I.; Maher, E.; Depinho, R.; Black, P. A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA as a mitogen in glioblastoma. Cancer Res 2006; 66(22): 10815-10823.

Chakravarti, A, Saia, G.; Zhang, M. Predictive and prognostic markers in prostate cancer. Curr Cancer Ther Rev. 2006 Nov;7(6):490-504.

Chakravarti, A.; Winter, K., Wu, C-L; Kaufman, D.; Hammond, E.; Parliament, M.; Tester, W.; Hagan, M.; Grignon, D.; Heney, N.; Pollack, A.; Sandler, H.; Shipley, W. Expression of the Epidermal Growth Factor Receptor (EGFR) is Associated with Improved Outcome in Muscle-Invading Bladder Cancer. Int J. Rad Oncol Biol Phys. 2005 Jun 1; 62(2): 309-317.

Chakravarti, A. ; Seiferheld, W.; Tu, X.; Wang, H.; Zhang, H.; Ang, K.K.; Hammond, E.; Curran, W.; Mehta, M. Immunohistochemically-Determined Total Epidermal Growth Factor Receptor (EGFR) Levels are not of Prognostic Value in Newly-Diagnosed Glioblastoma Multiforme (GBM): A Report from the Radiation Therapy Oncology Group (RTOG). Int J. Rad Oncol Biol Phys. 2005 Jun 1; 62(2):318-327.

Zhang, M.; Latham, D.E.; Delaney, M.A.; Chakravarti, A.*. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005 Apr 7; 24(15): 2474-2482. * AC is senior/corresponding author.

Nguyen, P.; Chakravarti, A.; Batchelor, T.; Hochberg , F.; Loeffler, J. Results of Whole- Brain Radiation as Salvage of Methotrexate Failure in Patients with Primary Central Nervous System Lymphoma. J Clin Oncol 2005 Mar 1; 23(7):1507-1513.

Zhang, M., Mukherjee, N., Bermudez, R.S., Latham, D.E., Delaney, M.A., Zietman, A.L., Shipley, W.U., Chakravarti, A.* Adenovirus-mediated Inhibition of Survivin Expression Sensitizes Human Prostate Cancer Cells to Paclitaxel In Vitro and In Vivo. Prostate 2005 Aug 1;64(3):293-302.

Henson JW, Hobbs W, Chakravarti A, Louis DN. Cellular and genetic changes in malignant gliomas following irradiation in patients requiring early reresection of progressive tumor. J. Neurooncol 2005 Sept;74(2):151-4.

Chakravarti, A.; Zhai, G.; Suzuki, Y.; Sarkesh, S.; Black, P.; Muzikansky, A. ; Loeffler, J. The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas. J Clin Oncol 2004 May 15;22(10):1926-33.

Nestler U, Wakimoto H, Siller-Lopez F, Aguilar LK, Chakravarti A, Muzikansky A, Stemmer-Rachamimov A, Chiocca EA, Aguilar-Cordova E, Hochberg FH. The combination of adenoviral HSV TK gene therapy and radiation is effective in athymic mouse glioblastoma xenografts without increasing toxic side effects. J Neurooncol. 2004 Mar-Apr;67(1-2):177-88.

Chakravarti, A.; Zhai, G.; Zhang, M., Malhotra, R.; Latham, D., Delaney, M., Robe, P.; Nestler, U.; Loeffler, J. Survivin Enhances Radiation Resistance in Primary Human Glioblastoma Cells via Caspase-Independent Mechanisms. Oncogene. 2004 Sep 30;23(45):7494-506.

Chakravarti, A.; Dicker, A.; Mehta, M. The contribution of Epidermal Growth Factor Receptor (EGFR) signaling pathway to radioresistance in human gliomas: A review of preclinical and correlative clinical data. Int J Rad Onc Biol Phys 2004; 58(3): 927-931.

Chakravarti, A.; Heydon, K.; Wu, C-L; Hammond, E.; Pollack, A.; Roach, M.; Wolkov, H.; Okunieff, P; Komaki, R.; Fontanesi, J; Abrams, R.; Pilepich, M.; Shipley, W. Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: An analysis from RTOG 86-10. J Clin Oncol 2003;

Chakravarti, A. And Zhai GG. Molecular and prognostic factors of prostate cancer. World J. Urol. 2003; 21(4):265-274.

Chakravarti, A. ; Loeffler, J. S. ; Dyson, N..J. Insulin-like growth factor receptor I (IGFRI) mediates resistance to anti-epidermal growth factor receptor (EGFR) therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 2002; 62(1):200-207.

Chakravarti, A.; Noll, E.; Black, P.B.; Dyson, N.J.; Loeffler, J.S. Quantitatively-determined Survivin expression levels are of prognostic value in human gliomas. J Clin Oncol. 2002; 20(4):1063-1068

Chakravarti, A.; Chakladar, A.; Delaney, M.A.; Latham, D.E.; Loeffler, J.S. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res. 2002; 62(15):4307-4315

Chakravarti, A.; Delaney, M.D.; Noll, E.; Loeffler, J.S.; Black, P.B.; Dyson, N.J. Prognostic and pathologic significance of protein expression profiling in human gliomas. Clinical Cancer Research 2001; 7:2387-2395.

Chakravarti et al. Young Investigators Workshop - Radiation Research Program, Radiation Oncology Sciences Program, NCI-HIH. Int J Rad Onc Biol Phys 2001; 49(5): 1505-1516.

Okunieff, P.; Hammond, E.; Grignon, D.; Langer, C.; Pajak, T.F.; Ang, K.; Bruner, D.W.; Travis, E.; Greven, K.; Guha, A.; Moulder, J.; Pollack, A.; Scarantino, C.; Sneige, N.; Watson, J.; Amin, M.; Bondy, M.; Chakravarti, A.; Chapman, J.D.; Dicker, A.; Harris, J.; Koch, W.; Komaki, R.; Lange, C.; McBride, W.; Mitchell, J.; Milas, L.; Movsas, B.; Pandya, K.; Pienta, K.; Regine, W.; Ritter, M.; Rubin, P.; Safran, H.; Sauter, E.; Schell, M.; Stevens, C.; Trotti, A.; Vikram, B. Translational Research Program. Int J Radiat Oncol Biol Phys 2001; 51(3 suppl 2): 75-87.

Chakravarti, A.; Blanton, S.; Kendall, B.J.; McCallum, R.W. Cosegregation of familial pseudoobstruction and presence of digital arches in a large multigenerational pedigree. Digestive Diseases and Sciences 1996; 41(7):1429-1433.

Kendall, B.J.; Chakravarti, A.; Kendall, E.; McCallum, R.W. The effect of intravenous erythromycin on solid meal gastric emptying in patients with chronic symptomatic post-vagotomy-antrectomy gastroparesis. Aliment. Pharmacol. Ther. 1997; 11(2):381-385.

Lazar, A.; Winter, M.R.; Nogueira, C.; Larson, P.; Finnemore, E.; Dolan, R.W.; Fuleihan, N.; Chakravarti, A.; Zietman, A.; Rosenberg, C. Loss of heterozygosity at chromosome 11q23 in SCC of the head and neck is associated with recurrent disease. Clinical Cancer Research 1998; 4(11):2787-2793.

Chakravarti, A.; Constable, W.C.; Tegtmeyer, C.; Kelly, M. Ir-192 brachytherapy in the management of primary bile duct tumors. Applied Radiology 1999; 28(4): 22-26.

Chakravarti, A.; Compton, C.C.; Shellito, P.C.; Wood, W.C.; Landry, J.; Machuta, S.R.; Kaufman, D.; Ancukiewicz, M.; Willett, C.G. Long-term follow-up of patients with rectal cancer managed by local excision with and without adjuvant therapy. Annals of Surgery 1999; 230(1): 49-54.

Chakravarti, A.; Spiro, I.T.; Hug, E.B.; Mankin, H.J.; Suit, H.D. Radiation therapy in the management of giant cell tumor of bone. J. of Bone and Joint Surgery 1999; 81A: 1566-1573.

Chakravarti, A.; Zehr, E.; Zietman, A.L.; Shipley, W.U.; Wu, C.L. Thymosin b15 predicts for distant failure for patients with clinically localized prostate cancer. Urology 2000; 55(5):635-638.

Chakravarti, A. Co-Author and Discussant- Case records of the Massachusetts General Hospital. Case 18-2000. A 45-year-old woman with a thoracic mass and Pancoast's syndrome. New England Journal of Medicine 2000; 342(24): 1814-1821.

Referrals to MGH BTC or MGH Neurosurgery